ASCO GU Symposium Announces New Findings on Tumor Reduction and Survival Outcomes in Advanced Renal Cell Carcinoma
The latest analysis, presented Feb. 13-14 at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025), further solidifies the effectiveness of the lenvatinib (Lenvima) and pembrolizumab (Keytruda) combination in treating this aggressive form of kidney cancer. Hutson played a key role in the study and provided insights into the impact of these findings.
“This analysis reinforces that greater tumor shrinkage correlates with improved survival outcomes,” Hutson said. “We now have compelling evidence that reducing overall tumor burden not only extends survival but also enhances the effectiveness of subsequent treatments, setting patients up for better long-term prognoses.”
The study, which initially led to the FDA approval of lenvatinib plus pembrolizumab for advanced renal cell carcinoma in 2021, continues to provide valuable insights into treatment strategies. The new findings demonstrate that patients with greater reductions in total tumor size at disease progression had significantly longer median survival rates. Additionally, data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) show that patients receiving the combination therapy were more likely to maintain or improve their IMDC risk scores, further supporting the regimen’s impact on long-term survival.
“These findings emphasize the importance of aggressive tumor reduction in the fight against renal cell carcinoma,” Hutson added. “The data suggest that this combination therapy offers the best outcomes among currently available treatments, making it a strong contender for first-line treatment in advanced renal cell carcinoma.”
TTUHSC and UMC Health System remain committed to advancing cancer treatment and improving patient outcomes through innovative research and clinical excellence.
About Texas Tech University Health Sciences Center
TTUHSC is a medical education, research and patient care leader dedicated to improving health outcomes across Texas and beyond.
About UMC Health System
UMC Health System is a nationally recognized academic medical center committed to delivering advanced patient care, innovative research and comprehensive cancer treatment.
Related Stories
Project Team Analyzing Survey Results to Increase TTUHSC Grant Funding Capacity
A project team conducted a capacity-building study during the last year aimed at increasing TTUHSC's overall NIH funding. The team is led by Lance McMahon, Ph.D.
NIH-Funded Exploratory Study to Seek Possible Targets for Treating Alcohol Use Disorder
In an effort to uncover therapeutic targets of AUD, the National Institute on Alcohol Abuse and Alcoholism at the NIH awarded a two-year, $407,468 grant to Dawei Li, Ph.D., from the TTUHSC School of Medicine and GSBS.
AAAS Recognizes Mitra for Mentorship Work
Amal Mitra, Dr.P.H., professor in TTUHSC's Julia Jones Matthews School of Population and Public Health, was recognized by the AAAS for his work with the AAAS HBCU Making and Innovation Initiative.
Recent Stories
NIH-Funded Exploratory Study to Seek Possible Targets for Treating Alcohol Use Disorder
In an effort to uncover therapeutic targets of AUD, the National Institute on Alcohol Abuse and Alcoholism at the NIH awarded a two-year, $407,468 grant to Dawei Li, Ph.D., from the TTUHSC School of Medicine and GSBS.
AAAS Recognizes Mitra for Mentorship Work
Amal Mitra, Dr.P.H., professor in TTUHSC's Julia Jones Matthews School of Population and Public Health, was recognized by the AAAS for his work with the AAAS HBCU Making and Innovation Initiative.
Summer Program Introduces Medical Students to the Research Laboratory
Each year, approximately 100 first-year TTUHSC School of Medicine students — more than half of the Lubbock class — step out of the classroom and into the laboratory to spend part of their summer making unique discoveries through the Medical Student Summer Research Program (MSSRP).